Abbvie to record $3.5 bln charge related to schizophrenia drug
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.
AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel Drug
AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .
AbbVie sees $3.5B impairment charge related to emraclidine
In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the
AbbVie to record $3.5B impairment charge for Cerevel drug
AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, which it acquired through its acquisition of Cerevel Therapeutics last year. The drugmaker disclosed in November that two Phase 2 studies of the drug failed to meet their primary endpoint.
Abbvie to record $3.5 billion charge related to schizophrenia drug
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies. AbbVie has been spending significantly on deals as its blockbuster rheumatoid arthritis drug,
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug
Key Takeaways AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics.The biotech company reported in November that the schizophrenia drug,
FierceBiotech19h
AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...
AbbVie Inc. stock underperforms Friday when compared to competitors
This was the stock's fourth consecutive day of losses.
BioSpace18h
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
AbbVie's Stock Is Unfairly Cheap
The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...
bovnews17h
AbbVie Inc (ABBV) Reported a 30.61% Operating Margin Last Year—What’s the Real Story?
AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...
FierceBiotech3d
AbbVie exercises first $40M option to advance Capsida-partnered CNS gene therapy
Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...
AbbVie Inc. stock outperforms competitors despite losses on the day
This was the stock's third consecutive day of losses.
AbbVie’s Strategic Acquisition and Long-Term Growth Potential Justify Buy Rating Despite Short-Term EPS Adjustments
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...
AbbVie Unusual Options Activity For January 10
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...